Chennai: India’s indigenous COVID-19 vaccine Covaxin’s first phase of human clinical trials have begun in SRM Medical College Hospital and Research Centre in Chennai on Thursday.
The Indian Council of Medical research had chosen SRM out of 12 institutions to conduct the trials for the vaccine. The vaccine has been developed by Hyderabad-based Bharat Biotech in collaboration with ICMR and the National Institute of Virology.
“The vaccine received DCGI approval for phase-1 and 2 human clinical trials and the trials will commence across India from July 2020,” read Bharat Biotech’s website.
” The indigenous, inactivated vaccine is developed and manufactured in Bharat Biotech’s BSL-3 (Bio-Safety Level 3) high containment facility,” it said.